Skip to main navigation

Overview
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials
- SEC Filings
- Quarterly Results
Governance
IR Resources

Breadcrumb

Home
5
Investor Relations
5
Quarterly Results

Quarterly Results

Show all

2022

Q2 Earnings Releases

Webcast
Press Release

Q1 Earnings Releases

Webcast
Press Release

2021

Q4 Earnings Releases

Webcast
Press Release
4Q21 Earnings Script 190.1 KB

Q3 Earnings Releases

Webcast
Press Release

Q2 Earnings Releases

Webcast
Press Release

Site - Investor Tools

Site - Footer Menu 1

Platform

Technology
Capabilities

Site - Footer Menu 2

Clinical

Oncology
Inherited Disorders

Site - Footer Menu 3

BioPHARMA

RESOURCES

Site - Footer Menu 4

Company

About Us
Team
Investors
Blog, News & Events
Careers
Contact

© 2022 SOPHiA GENETICS. All rights reserved.

Site - Footer Copyright

Privacy Policy | Terms of Use | Legal

Site - Footer Social

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA Hereditary Cancer Solution, SOPHiA Myeloid Solution, SOPHiA Solid Tumor Solution are available as CE-IVD product for In Vitro Diagnostic Use in Europe, Turkey and Israel. Information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at support@sophiagenetics.com to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.